Efficacy Study of RX-10100 to Treat Erectile Dysfunction (ED)

Erectile Dysfunction (ED) Clinical Trial

Official title: A Double-Blinded, Randomized, Placebo-Controlled, Dose-Exploring Study of RX-10100 for Eight Weeks of On-Demand Administration in Subjects With Erectile Dysfunction (ED)

Status Completed

Clinical Trial Summary

The primary objective of this Phase IIa trial is to determine the effective doses and treatment period for an upcoming RX-10100 Phase IIb trial in subjects with erectile dysfunction (ED). The secondary objectives of this trial are to evaluate the safety and the quality of life in subjects with ED receiving RX-10100 treatment.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Erectile Dysfunction
• Erectile Dysfunction (ED)

• NCT number: NCT00693056
• Study type: Interventional
• Source: Rexahn Pharmaceuticals, Inc.
• Status: Completed
• Phase: Phase 2
• Start date: June 2008
• Completion date: May 2009